Bellah Sm Faysal, Salam Md Abdus, Billah S M Saker, Karim Md Rezaul
School of Life Science, University of Science and Technology of China, Hefei, P.R. China.
Department of Surgical Oncology, National Institute of Cancer Research & Hospital, Mohakhali, Bangladesh.
Ann Hum Biol. 2023 Feb;50(1):63-74. doi: 10.1080/03014460.2023.2171122.
and are biologically potential genes responsible for prostate cancer.
We aimed to analyse the expression and association of and genes in prostate cancer.
Web-based bioinformatics tools were used to assess the association of and genes with prostate cancer risks. A case-control study of 210 prostate cancer cases and 207 controls was also approved to determine the allelic variants of the gene- rs2740574 () and the variant of gene-rs776746 () using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP). The risk of prostate cancer was estimated as odds ratio (OR) and 95% confidence interval (CI) using unrestricted logistic regression models.
Our data confirmed that both and genes are significantly associated with higher prostate cancer risks. In the case of polymorphism, the heterozygote (*1 A/*1B), mutant (*1B/*1B), and combined heterozygote plus mutant (*1A/*1B+*1B/*1B) genotypes showed 3.52-fold, 3.90-fold, and 3.67-fold increased risk of prostate cancer, respectively. In the case of polymorphism, the heterozygote (*1/*3), mutant (*3/*3), and combined (*1/*3+*3/*3) genotypes were found to be significantly associated with 5.11-, 5.49-, and 5.28-fold greater risk of prostate cancer, respectively.
Our results indicate that and are significantly associated with increased prostate cancer risk.KEY MESSAGESBioinformatics tools were used and concluded that the and genes were significantly associated with the development and progression of prostate cancer. and polymorphisms were significantly associated with an increased risk of prostate cancer.Polymerase Chain Reaction (PCR)-Restriction Fragment Length Polymorphism (RFLP) was used to estimate polymorphisms of prostate cancer progression in the Bangladeshi population.
[基因名称1]和[基因名称2]是与前列腺癌相关的具有生物学潜力的基因。
我们旨在分析[基因名称1]和[基因名称2]基因在前列腺癌中的表达及相关性。
使用基于网络的生物信息学工具评估[基因名称1]和[基因名称2]基因与前列腺癌风险的相关性。一项包含210例前列腺癌病例和207例对照的病例对照研究也获批准，采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）技术来确定[基因名称1]基因的等位基因变体rs2740574（[具体突变形式1]）和[基因名称2]基因的变体rs776746（[具体突变形式2]）。使用非限制性逻辑回归模型，将前列腺癌风险估计为比值比（OR）和95%置信区间（CI）。
我们的数据证实，[基因名称1]和[基因名称2]基因均与较高的前列腺癌风险显著相关。就[基因名称1]多态性而言，杂合子（*1A/*1B）、突变体（*1B/*1B）以及杂合子加突变体组合（*1A/*1B+*1B/*1B）基因型的前列腺癌风险分别增加了3.52倍、3.90倍和3.67倍。就[基因名称2]多态性而言，杂合子（*1/*3）、突变体（*3/*3）以及组合基因型（*1/*3+*3/*3）分别与前列腺癌风险增加5.11倍、5.49倍和5.28倍显著相关。
我们的结果表明，[基因名称1]和[基因名称2]与前列腺癌风险增加显著相关。
关键信息
使用了生物信息学工具并得出结论，[基因名称1]和[基因名称2]基因与前列腺癌的发生和进展显著相关。
[基因名称1]和[基因名称2]多态性与前列腺癌风险增加显著相关。
采用聚合酶链反应（PCR）-限制性片段长度多态性（RFLP）技术来估计孟加拉人群中前列腺癌进展的多态性。
Zotero 插件